Mechanisms of camptothecin resistance by human topoisomerase I mutations

Journal of Molecular Biology

Volumn 339, Issue 4, 2004, Pages 773-784

  Chrencik, Jill E ^a   Staker, Bart L ^b   Burgin, Alex B ^b   Pourquier, Philippe ^c,e   Pommier, Yves ^c   Stewart, Lance ^b   Redinbo, Matthew R ^a,d  

^a University of North Carolina at Chapel Hill   (United States)

^b DeCODE Chemistry & Biostructures   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e INSTITUT BERGONIÉ   (France)

Author keywords

cancer; protein DNA complex; resistance; topo, I, human topoisomerase I; topo70, 70 kDa fragment of human topoisomerase I; topoisomerase; X ray crystallography

Indexed keywords

ASPARAGINE; CAMPTOTHECIN; DNA; DNA TOPOISOMERASE; PHENYLALANINE; SERINE; TOPOTECAN; WATER;

AMINO ACID SUBSTITUTION; ARTICLE; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG MECHANISM; HUMAN; HYDROPHOBICITY; MOLECULE; MUTATION; PRIORITY JOURNAL; PROTEIN STRUCTURE;

EID: 2542425518     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2004.03.077     Document Type: Article

References (47)

1. Chang J.-Y., Liu J.-F., Juang S.-H., Liu T.-W., Chen L.-T. Novel mutation of topoisomerase I in rendering cells resistant to camptothecin. Cancer Res. 62:2002;3716-3721
2. Vanhoefer U., Harstick A., Achterrath W., Cao A., Seeber S., Rustum Y.M. Irinotecan in the treatment of colorectal cancer: clinical overview. J. Clin. Oncol. 19:2001;1501
3. Gore M., Huinink W., Carmichael J., Gordon A., Davidson N., Coleman R., et al. Clinical evidence for topotecan-paclitaxel non-cross-resistance in ovarian cancer. J. Clin. Oncol. 19:2001;1893-1900
4. Rasheed Z.A., Rubin E.H. Mechanisms of resistance to topoisomerase I-targeting drugs. Oncogene. 22:2003;7296-7304
5. Pommier Y., Pourquier P., Urasaki Y., Wu J., Laco G.S. Topoisomerase I inhibitors: selectivity and cellular resistance. Drug Resist. Updates. 2:1999;307-318
6. Champoux J.J. DNA topoisomerases: structure, function, and mechanism. Annu. Rev. Biochem. 70:2001;369-413
7. Wang J.C. DNA Topoisomerases. Annu. Rev. Biochem. 65:1996;635-692
8. Stewart L., Ireton G.C., Champoux J.J. The domain organization of human topoisomerase I. J. Biol. Chem. 271:1996;7602-7608
9. Redinbo M.R., Stewart L., Kuhn P., Champoux J.J., Hol W.G. Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science. 279:1998;1504-1513
10. Stewart L., Redinbo M.R., Qiu X., Hol W.G.J., Champoux J.J. A model for the mechanism of human topoisomerase I. Science. 279:1998;1534-1541
11. Redinbo M.R., Stewart L., Champoux J.J., Hol W.G.J. Structural flexibility in human topoisomerase I revealed in multiple non-isomorphous crystal structures. J. Mol. Biol. 292:1999;685-696
12. Lesher D.-T.T., Pommier Y., Stewart L., Redinbo M.R. 8-Oxoguanine rearranges the active site of human topoisomerase I. Proc. Natl Acad. Sci. USA. 99:2002;12102-12107
13. Staker B.L., Hjerrild K., Feese M.D., Behnke C.A., Burgin A.B., Stewart L. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc. Natl Acad. Sci. USA. 99:2002;15387-15392
14. Redinbo M.R., Champoux J.J., Hol W.G.J. Novel insights into catalytic mechanism from a crystal structure of human topoisomerase I in complex with DNA. Biochemistry. 39:2000;6832-6840
15. Chrencik J.E., Burgin A.B., Pommier Y., Stewart L., Redinbo M.R. Structural impact of the leukemia drug 1-β-D-arabinofuranosylcytosine (Ara-C) on the covalent human topoisomerase I-DNA complex. J. Biol. Chem. 278:2003;12461-12466
16. Interthal H., Quigley P.M., Hol W.G.J., Champoux J.J. The role of lysine 532 in the catalytic mechanism of human topoisomerase I. J. Biol. Chem. 279:2004;2984-2992
17. Stewart L., Ireton G.C., Parker L.H., Madden K.R., Champoux J.J. Biochemical and biophysical analyses of recombinant forms of human topoisomerase I. J. Biol. Chem. 271:1996;7593-7601
18. Hsiang Y.H., Hertzberg R., Hecht S., Liu L.F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 260:1985;14873-14878
19. Hertzberg R.P., Caranfa M.-J., Hecht S.M. On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry. 28:1989;4629-4638
20. Fiorani P., Bruselles A., Falconi M., Chillemi G., Desideri A., Benedetti P. Single mutation in the linker domain confers protein flexibility and camptothecin resistance to human topoisomerase I. J. Biol. Chem. 278:2003;43268-43275
21. Pourquier P., Pommier Y. Topoisomerase I-mediated DNA damage. Advan. Cancer Res. 80:2001;189-216
22. Fertala J., Vance J.R., Pourquier P., Pommier Y., Bjornsti M.A. Substitutions of Asn-726 in the active site of yeast DNA topoisomerase I define novel mechanisms of stabilizing the covalent enzyme-DNA intermediate. J. Biol. Chem. 275:2000;15246-15253
23. Pourquier P., Ueng L.-M., Fertala J., Wang D., Park H.-J., Essigmann J.M., et al. Induction of reversible complexes between eukaryotic DNA topoisomerase I and DNA-containing oxidative base damages. 7, 8-dihydro-8-oxoguanine and 5-hydroxycytosine. J. Biol. Chem. 274:1998;8516-8523
24. Tamura H., Kohchi C., Yamada R., Ikeda T., Koiwai O., Patterson E., et al. Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites. Nucl. Acid Res. 19:1991;69-75
25. Saleem A., Ibrahim N., Patel M., Li X.G., Gupta E., Mendoza J., et al. Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning. Cancer Res. 57:1997;5100-5106
26. Li X., Haluska P., Hsiang Y.H., Bharti A.K., Kufe D.W., Liu L.F., Rubin E.H. Involvement of amino acids 361 to 364 of human topoisomerase I in camptothecin resistance and enzyme catalysis. Biochem. Pharmacol. 53:1997;1019-1027
27. Urasaki Y., Laco G.S., Pourquier P., Takebayashi Y., Kohlhagen G., Gioffre C., et al. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line. Cancer Res. 61:2001;1964-1969
28. Benedetti P., Fiorani L., Capuani L., Wang J.C. Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine. Cancer Res. 53:1993;4343-4348
29. Fiorani P., Amatruda J.F., Silvestri A., Butler R.H., Bjornsti M.-A., Benedetti P. Domain interactions affecting human DNA topoisomerase I catalysis and camptothecin sensitivity. Mol. Pharmacol. 56:1999;1105-1115
30. Urasaki Y., Laco G., Takebayashi Y., Baily C., Kohlhagen G., Pommier Y. Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site. Cancer Res. 61:2001;504-508
31. Tanizawa A., Pommier Y. Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture. Cancer Res. 52:1992;1848-1854
32. Tanizawa A., Bertrand R., Kohlhagen G., Tabuchi A., Jenkins J., Pommier Y. Cloning of Chinese hamster DNA topoisomerase I cDNA and identification of a single point mutation responsible for camptothecin resistance. J. Biol. Chem. 268:1993;25463-25468
33. Kubota N., Kanzawa F., Nishio K., Takedo Y., Ohmori T., Fujiwara Y., et al. Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line. Biochem. Biophys. Res. Commun. 188:1992;571-577
34. Bailly C., Carrasco C., Hamy F., Vezin H., Prudhomme M., Saleem, Rubin E. The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles. Biochemistry. 38:1999;8605-8611
35. Rubin E., Pantazis P., Bharti D., Toppmeyer D., Giovanella B., Kufe D. Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitro-camptothecin. J. Biol. Chem. 269:1994;2433-2439
36. Woo M.H., Losasso C., Guo H., Pattarello L., Benedetti P., Bjornsti M.-A. Locking the DNA topoisomerase I protein clamp inhibits DNA rotation and induces cell lethality. Proc. Natl Acad. Sci. USA. 100:2003;13767-13772
37. Carey J.F., Schultz S.J., Sisson L., Fazzio T.G., Champoux J.J. DNA relaxation by human topoisomerase I occurs in the closed clamp conformation of the protein. Proc. Natl Acad. Sci. USA. 100:2003;5640-5646
38. Burgin A.B. Synthesis and use of DNA containing a 5′-bridging phosphorothioate as a suicide substrate for type I DNA topoisomerases. Methods Mol. Biol. 95:2002;119-128
39. Burgin A.B., Huizenga B., Nash H. A novel suicide substrate for DNA topoisomerases and site-specific recombinases. Nucl. Acid Res. 23:1995;2973-2979
40. Otwinowski Z., Minor W. Macromolecular crystallography. Methods in Enzymology. Part A. vol. 276:1997;Academic Press, New York. pp. 307-326
41. Navaza J., Saludjian P. AMoRe: an automated molecular replacement package. Acta Crystallog. sect. D. 57:1997;1367-1372
42. Brunger A.T. Assessment of phase accuracy by cross validation: the free R-value. Methods and applications. Acta Crystallog. sect. D. 49:1993;24-36
43. Esnouf R.M. Further additions to MolScript version 1.4, including reading and contouring of electron-density maps. Acta Crystallog. D Biol. Crystallog. 55:1999;938-940
44. Kraulis P.J. Moscript: a program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallog. 24:1991;946-950
45. Merritt E.A., Bacon D.J. Raster 3D: photorealistic molecular graphics. Methods Enzymol. 277:1997;505-524
46. Fujimori A., Harker W.G., Kohlhagen G., Hoki Y., Pommier Y. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res. 55:1995;1339-1346
47. Woo M.H., Vance J.R., Marcos A.R., Bailly C., Bjornsti M.-A. Active site mutations in DNA topoisomerase I distinguish the cytotoxic activities of camptothecin and the indolocarbazole, rebeccamycin. J. Biol. Chem. 277:2002;3813-3822